Le Lézard
Classified in: Health
Subject: PDT

MigraKet® Now Available for Purchase, Offering Innovative Migraine Management Formulation for 15% of Americans who Suffer from Migraine


Available in the U.S., Swiss-Guided MigraKet® provides game-changing approach

BASEL, Switzerland, May 28, 2024 /PRNewswire/ -- International wellness brand Brain Ritual proudly announces the availability of MigraKet® on its online platform, migraket.com. This groundbreaking migraine management formulation, developed by renowned neuroscientist Dr. Elena Gross, PhD, offers hope and relief to individuals grappling with this debilitating condition.

MigraKet® represents a paradigm shift in migraine management, addressing a potential root cause rather than merely alleviating symptoms. Backed by scientific evidence suggesting a link between migraine and impaired brain metabolism, MigraKet® offers a holistic approach to restoring brain energy metabolism and enhancing mitochondrial function. By providing the brain with bioactive ketone bodies and other crucial micronutrients, MigraKet® offers a sustainable approach to promoting overall brain health.

"There is mounting evidence pointing to metabolic dysfunction as a significant factor in migraine etiology," explains Dr. Gross. "MigraKet® is designed to target these underlying metabolic issues and the unique nutritional needs of migraine sufferers, offering an effective management formulation. Unlike traditional therapies that simply attempt to subside pain, MigraKet® supports whole body wellness."

New research shows that the occurrence of migraine can be a byproduct of inefficient energy production in the brain. MigraKet® is scientifically formulated with high-quality, bio-identical nutrients and bioactive ketone bodies to support optimal brain function. By managing the trigger mechanisms, MigraKet® empowers individuals to take control of their health and reclaim their lives from the grip of migraine.

"We know individuals do not want to play 'whack a mole' with their bodies anymore; addressing symptoms with medications that create new challenges and issues," says Dr. Gross. "A migraine is a critical alarm signaling imbalance in the brain and the body, for example an energy deficiency in the brain. Rather than hitting snooze, MigraKet® allows sufferers to manage potential metabolic deficiencies straight on."

The MigraKet® 15-day system is available for purchase on BrainRitual.com for $98. Each package includes 30 water-soluble powder sachets, designed for convenient daily use. For optimal results, MigraKet® should be taken twice daily for four weeks and may be used as a replacement for a daily multivitamin.

"MigraKet® represents more than just a product?it's a beacon of hope for those living with migraine," Dr. Gross emphasizes. "We invite individuals to join us on this journey toward better migraine management and improved quality of life."

For more information and to purchase MigraKet, please visit https://www.migraket.com/.

About Brain Ritual:
Brain Ritual is a pioneering health and wellness brand created by KetoSwiss, a Swiss company dedicated to harnessing the power of neuroscience to enhance human well-being. Led by Dr. Elena Gross, PhD, KetoSwiss is committed to developing innovative solutions that empower individuals to optimize their mental and physical health.

Note to Editors: Please contact [email protected] for inquiries or to arrange an interview with Dr. Elena Gross, PhD, or for samples. High-resolution images and additional materials are available upon request.

Media contact
[email protected] 

SOURCE Brain Ritual


These press releases may also interest you

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...

3 jui 2024
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...

3 jui 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...

3 jui 2024
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...



News published on and distributed by: